Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
Price : $35 *
At a glance
- Drugs Nevanimibe (Primary)
- Indications Adrenocortical carcinoma
- Focus Adverse reactions; First in man
- Sponsors Millendo Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 02 Nov 2017 Status changed from recruiting to completed.
- 06 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.